NMPA accepts clinical trial application for monkeypox vaccine
chinadaily.com.cn |
Updated: 2023-07-14 19:44
Share
Share - WeChat
The National Medical Products Administration (NMPA) has, on Thursday, officially accepted the clinical trial application for the replication-deficient monkeypox vaccine developed by China National Pharmaceutical Group Corporation (Sinopharm) Beijing Institute of Biological Products.
- HK bets on integrated hub to enhance TCM profile
- China widens net in battle against graft
- New US dietary guidelines trigger widespread concern
- China eyes space leap with record satellite filings
- Team formed to investigate the loss of 29 cultural relics
- Investigation into school uniforms confirms safety of waterproof layer
